Abstract
Background
Diabetic foot ulcers (DFUs) are a serious complication of diabetes, often leading to amputations and high healthcare costs. Dipeptidyl peptidase-4 (DPP-4) inhibitors may help wound healing by enhancing angiogenesis. This study aimed to evaluate the efficacy of DPP-4 inhibitors in DFUs healing.
Methods
This systematic review and meta-analysis followed PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing DPP-4 inhibitors with standard care or placebo were searched in PubMed, Scopus, Web of Science, and Cochrane Library up to October 1, 2025. Relative risk (RR) and mean difference (MD) were pooled using a random-effect model
Results
Four RCTs with 285 patients were included. DPP-4 inhibitors significantly increased complete ulcer healing (RR = 1.63, 95% CI 1.30-2.06, P < .0001) and shortened healing time (MD = −10.72 days, 95% CI −14.61 to −6.84, P < .00001). Ulcer size was also reduced (MD = −2.36 cm2, 95% CI −2.95 to −1.77, P < .00001). Side effects were rare and similar between groups.
Conclusion
Treatment with DPP-4 inhibitors improves DFU healing outcomes compared to the control group. This finding is limited to the number of included studies and the small sample size. Future randomized clinical trials are warranted to provide more robust results.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
